<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02300220</url>
  </required_header>
  <id_info>
    <org_study_id>14IC2031</org_study_id>
    <secondary_id>2012-002198-72</secondary_id>
    <nct_id>NCT02300220</nct_id>
  </id_info>
  <brief_title>Targeted Retreatment of COPD Exacerbations</brief_title>
  <official_title>Targeted Retreatment of Incompletely Recovered COPD Exacerbations With Ciprofloxacin: a Double-blind, Randomised, Placebo-controlled, Multicentre Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effects of targeted re-treatment of patients who do not recover&#xD;
      from an exacerbation of COPD. Half of the patients will receive ciprofloxacin while the other&#xD;
      half will receive a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD is a long term lung condition where patients suffer recurrent symptom flare-ups, called&#xD;
      'exacerbations'. Patients who have lots of exacerbations have a worse quality of life, poorer&#xD;
      ability to breath, and may die earlier than those who don't. Previous research by our group&#xD;
      has shown that patients who have an exacerbation and have not completely recovered two weeks&#xD;
      after the start of treatment are more likely to suffer another one early than those who&#xD;
      completely recover.&#xD;
&#xD;
      This study aims to test whether we can prevent this early re-exacerbation by giving an extra&#xD;
      course of antibiotics, compared to a placebo. Patients who experience an exacerbation of COPD&#xD;
      and are treated with antibiotics will, two weeks after the start of their treatment, be&#xD;
      invited to attend a screening visit. Patients will be eligible for the study if they have not&#xD;
      fully recovered at this visit (i.e. if they either still have symptoms or if blood tests show&#xD;
      there is still inflammation present) and fulfil other diagnostic measures for COPD. Patients&#xD;
      will be allocated to the treatment groups at random, and if eligible will be treated with a&#xD;
      further 1 week of ciprofloxacin 500mg twice daily or a placebo.&#xD;
&#xD;
      Patients will then be followed up in the study for a further 3 months, and the primary study&#xD;
      outcome will be the time to the next exacerbation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2014</start_date>
  <completion_date type="Actual">January 22, 2019</completion_date>
  <primary_completion_date type="Actual">January 22, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the Next COPD Exacerbation</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>The primary outcome will be the time to the next COPD exacerbation following targeted retreatment with the IMP or placebo, censored at 90 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the Initial Exacerbation</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Secondary endpoints will include duration of the initial exacerbation following targeted retreatment with the IMP or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Non Fatal Adverse Events</measure>
    <time_frame>7 days of treatment</time_frame>
    <description>Secondary endpoints will include adverse events following targeted retreatment with the IMP or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lung Function</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Secondary endpoints will include changes from randomization to 90 days in FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have Resistance Bacteria in the Sputum</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Bacterial load and resistance Secondary endpoints will include resistance following targeted retreatment with the IMP or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Readmission</measure>
    <time_frame>90 days of treatment</time_frame>
    <description>Secondary endpoints will include hospital readmission following targeted retreatment with the IMP or placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg, twice daily for 1 week (oral).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one capsule, twice daily for 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>500 mg, twice daily for 1 week (oral)</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule, twice daily for 1 week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of COPD confirmed spirometrically at screening&#xD;
&#xD;
          2. COPD exacerbation with treatment commenced 14 days prior to study enrolment and&#xD;
             treated with 5-14 days of a non-quinolone antibiotic.&#xD;
&#xD;
          3. Exacerbation here will be defined as an episode of symptomatic worsening of COPD that&#xD;
             was treated by the patient's attending clinician. Confirmation of the initial&#xD;
             exacerbation diagnosis will be provided from the case notes, referral letter, or&#xD;
             directly from the treating clinician, and will be documented in the CRF.&#xD;
&#xD;
          4. Age: ≥ 45 years of age at screening.&#xD;
&#xD;
          5. Persistent symptoms and/or a CRP≥8mg/L when assessed 2 weeks after exacerbation onset&#xD;
&#xD;
          6. Able to complete questionnaires for health status and symptoms and keep written diary&#xD;
             cards&#xD;
&#xD;
          7. Severity of disease: Patients with a measured FEV1&lt;80% of predicted normal values at 2&#xD;
             weeks post exacerbation&#xD;
&#xD;
          8. Able and willing to give signed and dated written informed consent to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other clinically predominant chronic respiratory disease.&#xD;
&#xD;
          2. Intubated and receiving mechanical ventilation&#xD;
&#xD;
          3. Patients with known hypersensitivity to the antibiotic under evaluation, to other&#xD;
             quinolones or any excipients of the IMP/placebo.&#xD;
&#xD;
          4. Patients with a prior history of tendonopathy or tendon rupture&#xD;
&#xD;
          5. Elderly patients taking long term systemic corticosteroids&#xD;
&#xD;
          6. Patients on long term antibiotics for other conditions&#xD;
&#xD;
          7. Patient too unwell for randomisation, i.e. requiring retreatment in the judgment of&#xD;
             the study doctor&#xD;
&#xD;
          8. Female patients who are pregnant or planning on becoming pregnant during the study, or&#xD;
             are breastfeeding.&#xD;
&#xD;
          9. Patient taking clinically significant contraindicated medication as per the SmPC s,&#xD;
             such as use of concomitant tizanidine or methotrexate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wisia Wedzicha, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aintree University Hospital NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Georges University Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton and Harefield Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW36NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <results_first_submitted>November 7, 2019</results_first_submitted>
  <results_first_submitted_qc>February 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2021</results_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02300220/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02300220/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciproflaxacin</title>
          <description>Retreatment with Ciproflaxacin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Retreatment with Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not tolerate IMP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ciprofloxacin</title>
          <description>500 mg, twice daily for 1 week (oral).&#xD;
Ciprofloxacin: 500 mg, twice daily for 1 week (oral)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>one capsule, twice daily for 1 week.&#xD;
Placebo: One capsule, twice daily for 1 week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.1" spread="8.8"/>
                    <measurement group_id="B2" value="69.1" spread="7.4"/>
                    <measurement group_id="B3" value="69.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to the Next COPD Exacerbation</title>
        <description>The primary outcome will be the time to the next COPD exacerbation following targeted retreatment with the IMP or placebo, censored at 90 days.</description>
        <time_frame>Up to 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>500 mg, twice daily for 1 week (oral).&#xD;
Ciprofloxacin: 500 mg, twice daily for 1 week (oral)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one capsule, twice daily for 1 week.&#xD;
Placebo: One capsule, twice daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Next COPD Exacerbation</title>
          <description>The primary outcome will be the time to the next COPD exacerbation following targeted retreatment with the IMP or placebo, censored at 90 days.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="29" upper_limit="90"/>
                    <measurement group_id="O2" value="58" lower_limit="24.5" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary endpoint was assessed using a Cox's proportional hazard model with pre-specified adjustment for patient's self-reported history of exacerbations over the previous year and with stratification for study centre. The onset of exacerbation will be monitored up to 90 days or at patient withdrawal.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.764</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.071</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.684</ci_lower_limit>
            <ci_upper_limit>1.676</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of the Initial Exacerbation</title>
        <description>Secondary endpoints will include duration of the initial exacerbation following targeted retreatment with the IMP or placebo.</description>
        <time_frame>Up to 90 days</time_frame>
        <population>Missing participants data 16 for ciprofloxacin and 15 for placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>500 mg, twice daily for 1 week (oral).&#xD;
Ciprofloxacin: 500 mg, twice daily for 1 week (oral)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one capsule, twice daily for 1 week.&#xD;
Placebo: One capsule, twice daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of the Initial Exacerbation</title>
          <description>Secondary endpoints will include duration of the initial exacerbation following targeted retreatment with the IMP or placebo.</description>
          <population>Missing participants data 16 for ciprofloxacin and 15 for placebo</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.703</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Non Fatal Adverse Events</title>
        <description>Secondary endpoints will include adverse events following targeted retreatment with the IMP or placebo.</description>
        <time_frame>7 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>500 mg, twice daily for 1 week (oral).&#xD;
Ciprofloxacin: 500 mg, twice daily for 1 week (oral)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one capsule, twice daily for 1 week.&#xD;
Placebo: One capsule, twice daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Non Fatal Adverse Events</title>
          <description>Secondary endpoints will include adverse events following targeted retreatment with the IMP or placebo.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lung Function</title>
        <description>Secondary endpoints will include changes from randomization to 90 days in FEV1.</description>
        <time_frame>Baseline and 90 days</time_frame>
        <population>Only the participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>500 mg, twice daily for 1 week (oral).&#xD;
Ciprofloxacin: 500 mg, twice daily for 1 week (oral)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one capsule, twice daily for 1 week.&#xD;
Placebo: One capsule, twice daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lung Function</title>
          <description>Secondary endpoints will include changes from randomization to 90 days in FEV1.</description>
          <population>Only the participants who completed the study</population>
          <units>litres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0229" spread="0.199"/>
                    <measurement group_id="O2" value="0.0041" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.239</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have Resistance Bacteria in the Sputum</title>
        <description>Bacterial load and resistance Secondary endpoints will include resistance following targeted retreatment with the IMP or placebo.</description>
        <time_frame>Up to 90 days</time_frame>
        <population>Lower participants number due to the number of patients with a pathogenic organism with newly acquired ciprofloxacin resistance, present in a sputum sample collected at 90 days</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>500 mg, twice daily for 1 week (oral).&#xD;
Ciprofloxacin: 500 mg, twice daily for 1 week (oral)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one capsule, twice daily for 1 week.&#xD;
Placebo: One capsule, twice daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have Resistance Bacteria in the Sputum</title>
          <description>Bacterial load and resistance Secondary endpoints will include resistance following targeted retreatment with the IMP or placebo.</description>
          <population>Lower participants number due to the number of patients with a pathogenic organism with newly acquired ciprofloxacin resistance, present in a sputum sample collected at 90 days</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Readmission</title>
        <description>Secondary endpoints will include hospital readmission following targeted retreatment with the IMP or placebo.</description>
        <time_frame>90 days of treatment</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>500 mg, twice daily for 1 week (oral).&#xD;
Ciprofloxacin: 500 mg, twice daily for 1 week (oral)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one capsule, twice daily for 1 week.&#xD;
Placebo: One capsule, twice daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Readmission</title>
          <description>Secondary endpoints will include hospital readmission following targeted retreatment with the IMP or placebo.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days + 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ciprofloxacin</title>
          <description>500 mg, twice daily for 1 week (oral).&#xD;
Ciprofloxacin: 500 mg, twice daily for 1 week (oral)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>one capsule, twice daily for 1 week.&#xD;
Placebo: One capsule, twice daily for 1 week</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oncology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Abdominal Colic/Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Pain/Tendonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis/Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Jadwiga Wedzicha</name_or_title>
      <organization>Imperial College London</organization>
      <phone>02075947947</phone>
      <email>j.wedzicha@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

